These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 22301194)

  • 1. Effects of Food and Drug Administration-approved medications for Alzheimer's disease on clinical progression.
    Mielke MM; Leoutsakos JM; Corcoran CD; Green RC; Norton MC; Welsh-Bohmer KA; Tschanz JT; Lyketsos CG
    Alzheimers Dement; 2012 May; 8(3):180-7. PubMed ID: 22301194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longitudinal Neuropsychological Outcome in Taiwanese Alzheimer's Disease Patients Treated with Medication.
    Yang YH; Wu MN; Chou PS; Su HC; Lin SH; Sung PS
    Curr Alzheimer Res; 2018 Mar; 15(5):474-481. PubMed ID: 29032750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term associations between cholinesterase inhibitors and memantine use and health outcomes among patients with Alzheimer's disease.
    Zhu CW; Livote EE; Scarmeas N; Albert M; Brandt J; Blacker D; Sano M; Stern Y
    Alzheimers Dement; 2013 Nov; 9(6):733-40. PubMed ID: 23332671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CDR state transition probabilities in Alzheimer's disease with and without cholinesterase inhibitor intervention in an observational cohort.
    Bloudek LM; Spackman DE; Veenstra DL; Sullivan SD
    J Alzheimers Dis; 2011; 24(3):599-607. PubMed ID: 21297268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Butyrylcholinesterase K and Apolipoprotein E-ɛ4 Reduce the Age of Onset of Alzheimer's Disease, Accelerate Cognitive Decline, and Modulate Donepezil Response in Mild Cognitively Impaired Subjects.
    De Beaumont L; Pelleieux S; Lamarre-Théroux L; Dea D; Poirier J;
    J Alzheimers Dis; 2016 Oct; 54(3):913-922. PubMed ID: 27567841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data.
    Dysken MW; Guarino PD; Vertrees JE; Asthana S; Sano M; Llorente M; Pallaki M; Love S; Schellenberg GD; McCarten JR; Malphurs J; Prieto S; Chen P; Loreck DJ; Carney S; Trapp G; Bakshi RS; Mintzer JE; Heidebrink JL; Vidal-Cardona A; Arroyo LM; Cruz AR; Kowall NW; Chopra MP; Craft S; Thielke S; Turvey CL; Woodman C; Monnell KA; Gordon K; Tomaska J; Vatassery G
    Alzheimers Dement; 2014 Jan; 10(1):36-44. PubMed ID: 23583234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination Therapy of Cholinesterase Inhibitor (Donepezil or Galantamine) plus Memantine in the Okayama Memantine Study.
    Matsuzono K; Hishikawa N; Ohta Y; Yamashita T; Deguchi K; Nakano Y; Abe K
    J Alzheimers Dis; 2015; 45(3):771-80. PubMed ID: 25624417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interaction between vascular factors and the APOE ε4 allele in predicting rate of progression in Alzheimer's disease.
    Mielke MM; Leoutsakos JM; Tschanz JT; Green RC; Tripodis Y; Corcoran CD; Norton MC; Lyketsos CG
    J Alzheimers Dis; 2011; 26(1):127-34. PubMed ID: 21593560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FDA approves groundbreaking Alzheimer's drug.
    Provider; 2004 Feb; 30(2):24, 27. PubMed ID: 14964917
    [No Abstract]   [Full Text] [Related]  

  • 10. Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease.
    Lopez OL; Becker JT; Wahed AS; Saxton J; Sweet RA; Wolk DA; Klunk W; Dekosky ST
    J Neurol Neurosurg Psychiatry; 2009 Jun; 80(6):600-7. PubMed ID: 19204022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. APOE ε4 Carrier Status as Mediator of Effects of Psychotropic Drugs on Clinical Changes in Patients With Alzheimer's Disease.
    de Oliveira FF; de Almeida SS; Chen ES; Smith MC; Bertolucci PHF
    J Neuropsychiatry Clin Neurosci; 2022; 34(4):351-360. PubMed ID: 35272493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Concomitant Use of Cholinesterase Inhibitors or Memantine With Cognitive Decline in Alzheimer Clinical Trials: A Meta-analysis.
    Kennedy RE; Cutter GR; Fowler ME; Schneider LS
    JAMA Netw Open; 2018 Nov; 1(7):e184080. PubMed ID: 30646339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Memantine in Alzheimer's disease: experience in an Alzheimer's disease assessment unit.
    Sinforiani E; Pasotti C; Chiapella L; Malinverni P; Zucchella C
    Aging Clin Exp Res; 2012 Apr; 24(2):193-6. PubMed ID: 22842837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.
    Tariot PN; Farlow MR; Grossberg GT; Graham SM; McDonald S; Gergel I;
    JAMA; 2004 Jan; 291(3):317-24. PubMed ID: 14734594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial.
    Porsteinsson AP; Grossberg GT; Mintzer J; Olin JT;
    Curr Alzheimer Res; 2008 Feb; 5(1):83-9. PubMed ID: 18288936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Donepezil plus memantine versus donepezil alone for treatment of concomitant Alzheimer's disease and chronic obstructive pulmonary disease: a retrospective observational study.
    Cao Y; Qian L; Yu W; Li T; Mao S; Han G
    J Int Med Res; 2020 Feb; 48(2):300060520902895. PubMed ID: 32046559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contemporary issues in the treatment of Alzheimer's disease: tangible benefits of current therapies.
    Tariot PN
    J Clin Psychiatry; 2006; 67 Suppl 3():15-22; quiz 23. PubMed ID: 16649847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Effect of Memantine on Cognitive Function and Behavioral and Psychological Symptoms in Mild-to-Moderate Alzheimer's Disease Patients.
    Zhang N; Wei C; Du H; Shi FD; Cheng Y
    Dement Geriatr Cogn Disord; 2015; 40(1-2):85-93. PubMed ID: 26066622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Apolipoprotein E ɛ4 Carrier Status on Cognitive Response to Acetylcholinesterase Inhibitors in Patients with Alzheimer's Disease: A Systematic Review and Meta-Analysis.
    Cheng YC; Huang YC; Liu HC
    Dement Geriatr Cogn Disord; 2018; 45(5-6):335-352. PubMed ID: 30041236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential effects of current specific treatments on behavioral and psychological symptoms in patients with Alzheimer's disease: a 12-month, randomized, open-label trial.
    Cumbo E; Ligori LD
    J Alzheimers Dis; 2014; 39(3):477-85. PubMed ID: 24164733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.